Lusong Luo

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

Zhan Yao, Neilawattie M. Torres, Anthony Tao et al. · Cancer Cell · 2015 · 546 citations

Medicine, Cancer Biology, Oncology +17

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 372 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Yunhang Guo, Ye Liu, Nan Hu et al. · Journal of Medicinal Chemistry · 2019 · 349 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885

Alastair J. King, Denis R. Patrick, Roberta S. Batorsky et al. · Cancer Research · 2006 · 263 citations · Full text

Medicine, Oncology, Pharmacology +15

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 254 citations · Full text

Life Sciences, Molecular Biology, Oncology +17